GGrantIndex
← Search

Biologics Production Core

$143,546P01FY2011CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications & trials

Abstract

Core C is responsible for the production of clinical grade anfi-CD45 BCS antibody and anti CD20 1F5 antibody and their derivatization with DOTA and conjugation to streptavidin. These reagents will be produced, purified and vialed in the Biologies Production Facility of the Fred Hutchinson Cancer Research Center. In addition. Core C will be responsible for cGMP-compliant vialing of DOTA-biotin supplied in bulk form from a contract manufacturer (Macrocyclics, Inc.) Materials will be produced under current good manufactured practice (cGMP) conditions and Drug Master Files (DMFs) have been filed with the Food and Drug Administration (FDA).

View original record on NIH RePORTER →